MX2023003476A - Moduladores del receptor x2 de proteína g relacionado con mas y productos y métodos relacionados. - Google Patents
Moduladores del receptor x2 de proteína g relacionado con mas y productos y métodos relacionados.Info
- Publication number
- MX2023003476A MX2023003476A MX2023003476A MX2023003476A MX2023003476A MX 2023003476 A MX2023003476 A MX 2023003476A MX 2023003476 A MX2023003476 A MX 2023003476A MX 2023003476 A MX2023003476 A MX 2023003476A MX 2023003476 A MX2023003476 A MX 2023003476A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- mrgpr
- methods
- mas
- modulators
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063083638P | 2020-09-25 | 2020-09-25 | |
| US202163145407P | 2021-02-03 | 2021-02-03 | |
| US202163211987P | 2021-06-17 | 2021-06-17 | |
| PCT/US2021/052044 WO2022067094A1 (en) | 2020-09-25 | 2021-09-24 | Modulators of mas-related g-protein receptor x2 and related products and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003476A true MX2023003476A (es) | 2023-06-22 |
Family
ID=78302949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003476A MX2023003476A (es) | 2020-09-25 | 2021-09-24 | Moduladores del receptor x2 de proteína g relacionado con mas y productos y métodos relacionados. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11919864B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4217345A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023542541A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230097015A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116406357A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021347360A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3193207A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL301575A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023003476A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022067094A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202304729B (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021347360A1 (en) * | 2020-09-25 | 2023-05-25 | Escient Pharmaceuticals, Inc. | Modulators of mas-related g-protein receptor x2 and related products and methods |
| EP4232042A1 (en) * | 2020-10-21 | 2023-08-30 | Escient Pharmaceuticals, Inc. | Modulators of mas-related g-protein receptor x2 and related products and their use |
| PE20250789A1 (es) | 2022-03-30 | 2025-03-14 | Escient Pharmaceuticals Inc | Derivados de quinolina como moduladores del receptor x2 de la proteina g relacionados con mas y productos relacionados |
| CN115850250B (zh) * | 2022-10-25 | 2025-12-23 | 南京师范大学 | 一种可控可视化的一氧化碳释放剂及其制备方法和应用 |
| CN121532382A (zh) * | 2023-07-13 | 2026-02-13 | 北京普祺医药科技股份有限公司 | Mas相关g蛋白受体x2的拮抗剂及其用途 |
| US20250084063A1 (en) | 2023-08-18 | 2025-03-13 | Incyte Corporation | Bicyclic heterocycles as mrgprx2 antagonists |
| CN119504738A (zh) * | 2023-08-25 | 2025-02-25 | 武汉人福创新药物研发中心有限公司 | 作为mrgprx2拮抗剂的化合物及其制备方法和应用 |
| CN120118069A (zh) * | 2023-12-08 | 2025-06-10 | 武汉人福创新药物研发中心有限公司 | Mrgprx2拮抗剂及用途 |
| WO2025140279A1 (zh) | 2023-12-25 | 2025-07-03 | 上海森辉医药有限公司 | 季铵化合物及其药物用途 |
| CN120329282A (zh) * | 2024-01-17 | 2025-07-18 | 武汉人福创新药物研发中心有限公司 | Mas相关g蛋白受体x2拮抗剂及用途 |
| WO2025160430A1 (en) | 2024-01-25 | 2025-07-31 | Incyte Corporation | Bicyclic heterocycles as mrgprx2 antagonists |
| WO2025222040A1 (en) | 2024-04-19 | 2025-10-23 | Escient Pharmaceuticals, Inc. | Mrgprx2 modulators for use in treating mrgprx2 dependent conditions in subjects with low ige |
| WO2025223036A1 (zh) * | 2024-04-23 | 2025-10-30 | 凯复(苏州)生物医药有限公司 | Mrgprx2拮抗剂、包含其的药物组合物及其用途 |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
| WO2026009854A1 (ja) * | 2024-07-01 | 2026-01-08 | 日本たばこ産業株式会社 | ピリダジノン化合物及びその医薬用途 |
| US12630562B2 (en) | 2024-08-07 | 2026-05-19 | Arcus Biosciences, Inc. | Piperidylurea compounds and methods of use thereof |
| WO2026037254A1 (zh) * | 2024-08-10 | 2026-02-19 | 杭州英创医药科技有限公司 | 作为mrgprx2拮抗剂的化合物 |
| WO2026064344A1 (en) * | 2024-09-17 | 2026-03-26 | Solu Therapeutics, Inc. | Heterobifunctional molecules for binding mrgx2 and methods of treating medical conditions using same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030085005A (ko) | 2001-03-19 | 2003-11-01 | 니뽄 신야쿠 가부시키가이샤 | 진양제 |
| KR100957516B1 (ko) * | 2001-08-15 | 2010-05-14 | 이코스 코포레이션 | 2h-프탈라진-1-온 및 이것의 사용 방법 |
| US7320989B2 (en) * | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
| JP2006519258A (ja) * | 2003-02-28 | 2006-08-24 | エンサイシブ・ファーマシューティカルズ・インコーポレイテッド | ピリジン、ピリミジン、キノリン、キナゾリンおよびナフタレン系のウロテンシン−ii受容体拮抗薬 |
| US20070185079A1 (en) * | 2004-01-07 | 2007-08-09 | Astrazeneca Ab | Therapeutic agents I |
| JP2006124387A (ja) * | 2004-09-30 | 2006-05-18 | Taisho Pharmaceut Co Ltd | 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法 |
| CN102625799A (zh) * | 2009-06-25 | 2012-08-01 | 安姆根有限公司 | 杂环化合物及其用途 |
| AU2012335978A1 (en) * | 2011-11-08 | 2014-05-22 | Arena Pharmaceuticals, Inc. | Modulators of the G protein-coupled Mas receptor and the treatment of disorders related thereto |
| BR122021012629B1 (pt) * | 2013-02-01 | 2022-06-07 | Wellstat Therapeutics Corporation | Compostos de amina, composição compreendendo os referidos compostos e usos dos mesmos |
| AU2021347360A1 (en) * | 2020-09-25 | 2023-05-25 | Escient Pharmaceuticals, Inc. | Modulators of mas-related g-protein receptor x2 and related products and methods |
-
2021
- 2021-09-24 AU AU2021347360A patent/AU2021347360A1/en active Pending
- 2021-09-24 MX MX2023003476A patent/MX2023003476A/es unknown
- 2021-09-24 CA CA3193207A patent/CA3193207A1/en active Pending
- 2021-09-24 IL IL301575A patent/IL301575A/en unknown
- 2021-09-24 EP EP21795105.2A patent/EP4217345A1/en active Pending
- 2021-09-24 US US17/484,993 patent/US11919864B2/en active Active
- 2021-09-24 WO PCT/US2021/052044 patent/WO2022067094A1/en not_active Ceased
- 2021-09-24 KR KR1020237013945A patent/KR20230097015A/ko not_active Ceased
- 2021-09-24 CN CN202180075369.7A patent/CN116406357A/zh active Pending
- 2021-09-24 JP JP2023518858A patent/JP2023542541A/ja active Pending
-
2023
- 2023-04-24 ZA ZA2023/04729A patent/ZA202304729B/en unknown
- 2023-11-30 US US18/525,253 patent/US12275707B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022067094A1 (en) | 2022-03-31 |
| US11919864B2 (en) | 2024-03-05 |
| IL301575A (en) | 2023-05-01 |
| AU2021347360A9 (en) | 2024-02-08 |
| CA3193207A1 (en) | 2022-03-31 |
| JP2023542541A (ja) | 2023-10-10 |
| EP4217345A1 (en) | 2023-08-02 |
| ZA202304729B (en) | 2025-10-29 |
| AU2021347360A1 (en) | 2023-05-25 |
| US12275707B2 (en) | 2025-04-15 |
| KR20230097015A (ko) | 2023-06-30 |
| CN116406357A (zh) | 2023-07-07 |
| US20230065217A1 (en) | 2023-03-02 |
| US20240336570A1 (en) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021011647A (es) | Moduladores del receptor x4 de proteina g relacionado con mas y productos y metodos relacionados. | |
| WO2022061008A3 (en) | Modulators of mas-related g-protein receptor x4 and related products and methods | |
| MX2024013914A (es) | Moduladores del inflamasoma nlrp3 y productos y metodos relacionados | |
| ZA202200519B (en) | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents | |
| MX2024011933A (es) | Derivados de quinolina como moduladores del receptor x2 de la proteina g relacionado con mas y productos relacionados | |
| EA200870448A1 (ru) | Тризамещенные 1,2,4-триазолы | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| PH12023550130A1 (en) | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same | |
| PT2038290E (pt) | Moduladores de receptor do tipo toll 7 | |
| RU94044671A (ru) | Применение непептидных антагонистов рецептора тахикинина | |
| MX2022011712A (es) | Moduladores de receptor x4 de proteina g relacionado con mas y productos y metodos relacionados. | |
| CR20210007A (es) | Degradadores selectivos del receptor de estrógeno | |
| EA200500088A1 (ru) | Трициклические модуляторы ядерного рецептора стероидного гормона | |
| EA201071094A1 (ru) | Тризамещенные 1,2,4-триазолы в качестве модуляторов никотиновых ацетилхолиновых рецепторов | |
| MX2022006470A (es) | Tiromimeticos novedosos. | |
| ZA202400988B (en) | Aak1 inhibitor and use thereof | |
| CA2360308A1 (en) | Glucocorticoid receptor modulators | |
| MX2020002436A (es) | Antagonistas del receptor de vasopresina y productos y metodos relacionados a los mismos. | |
| MX2025010256A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| PH12022552561A1 (en) | Gip receptor agonist peptide compounds and uses thereof | |
| CR20220141A (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| MX2024003930A (es) | Moduladores de trpml, sus composiciones y metodos de uso. | |
| BR112023016459A2 (pt) | Métodos terapêuticos | |
| MX2025000071A (es) | Derivados de triazol como moduladores del receptor d de la proteína g relacionada con mas | |
| MX2023002068A (es) | Nuevos compuestos que tienen actividad inhibidora sobre el receptor de prostaglandina e2 y usos de los mismos. |